The upcoming film, The End of Medicine, addresses what our public health agencies ignore: the root causes of pandemics and how to prevent the next one. Contributions by CCS’s Dr. Aysha Akhtar, who served as a scientific advisor, are featured in the powerful production.
On March 24, 2022, CCS held our first ever Investor Summit. This event, the first of its kind in the field, brought together innovators, investors, researchers, start-ups, and venture philanthropists from around the world.
Over the past 20 years, an estimated 2 billion plus animals in the U.S. alone have been used in experimentation or to supply the biomedical industry. CCS published the "Animals in Laboratories Speak" booklet to commemorate World Day for Animals in Laboratories.
CCS's 2021 Year in Review
On March 24, 2022, CCS hosted its first ever Investor Summit in partnership with Beyond Animal. The Summit was open to the public and brought together an international group of innovators, investors, researchers, start-ups, and venture philanthropists.
CCS’s latest scientific publication on Parkinson’s Disease research
The House Energy and Commerce Health Subcommittee held a hearing on the FDA Modernization Act of 2021 as part of a larger legislative effort to promote innovation and the future of medicine.
Rep. Anna Eshoo of California responded to Dr. Aysha Akhtar and Dr. Paul Locke's op-ed in The Hill detailing a new governmental agency's need to embrace human-biology based testing methods to ensure its success in advancing medical science and improving human health.
The March 24 Summit is the premiere event focused on driving investment into testing methods that replace animal testing and that are more human-relevant.
The Center for Contemporary Sciences (CCS) is pleased to host its first Investor Summit 2022. This one-of-a-kind business development event, held in partnership with Beyond Animal, is open to the public and brings together an international group of innovators, investors, researchers, start-ups, and venture philanthropists.
The 1938 Federal Food, Drug, and Cosmetic Act requires that every drug be tested on animals — even though more than 90% of drugs found to be safe and effective in animals fail during human clinical trials, and even though safer and more effective methods of drug testing have been developed since then.
The creation of a new government agency, the Advanced Research Projects Agency for Health, has the potential to accelerate technologies based on human biology to the next level.
The Technologies We Promote Will Revolutionize Treatments, Advance Cures, Reduce Healthcare Cost and Improve the Quality of Life.
CCS and BICO formalized a strategic partnership aiming at modernizing drug development and replacing animal testing with more human-relevant methods.
We're excited to announce that we're partnering with MatTek Life Sciences. With their scientific and industry expertise and our mission to replace animal testing with better methods, our partnership will greatly advance our mutual goal of bringing better science and more human-relevant testing methods to the forefront.
New legislation will allow more innovative and human-relevant testing platforms to expedite the development of promising drugs.
Significant advancements have been made in medical research, such as the human body on chip technology that have the potential to better predict whether a drug will be safe and will work in humans than animal tests. But agencies such as the FDA must change their policies to allow more of these advancements to be used in place of artificial animal testing.
Join CCS in supporting the FDA Modernization Act of 2021
The FDA Modernization Act of 2021 amends the FFDCA by broadening options for drug development to include modern, innovative, human-relevant test methods. By doing so, this bill will speed up the discovery and lower the costs of new life-saving treatments.
In a major new development, the European Parliament resoundingly passed a resolution with a vote of 667 to 4 to phase out animal testing.
CCS welcomes two fantastic scientists who will lead the charge in supporting, promoting, and establishing the most innovative scientific tools that have the greatest ability to transform human health.
A curated list of scientific reports, white papers and videos for biomedical researchers and students on human-specific research methods, animal testing, and other relevant topics.
Sydney Lo, CCS's Science Intern, discusses her perspective on the lack of human-relevant testing methods throughout her academic career and the need to foster a future generation of scientists who understand the value of human-specific research methods in order to find the answers that animal models cannot give.
We’re proud to share that CCS has been recognized for its contribution to improve biomedical research by advancing human-specific research and testing methods.
Our Directory of Companies enables researchers, investors, and students to find collaborators to pioneer a paradigm shift towards testing methods that are based on human biology.
Our Directory of Academic Centers, including university-based initiatives and laboratories, enables researchers, investors, and students to find collaborators to pioneer a paradigm shift towards testing methods that are based on human biology.
Our Directory of Government and Nonprofit Agencies enables researchers, investors, and students to find collaborators to pioneer a paradigm shift towards testing methods that are based on human biology.
The Center for Contemporary Sciences announces the launch of a new international endeavor to improve human health: “Breakthroughs: Unlocking the Future of Medicine”.
The 2020 Annual Report for the Center of Contemporary Sciences
CCS is announcing a new partnership with GlassWall Syndicate to provide funding to companies developing alternatives to animal testing.
Dr. Akhtar discusses how the late Representative Alcee Hastings' legacy, the Humane Research and Testing Act (HRTA) of 2021, will provide a much needed boost to innovate biomedical science.
CCS is partnering with GlassWall Syndicate with an investment opportunity for companies developing alternatives to animal testing.
CCS is proud to announce its partnership with the GlassWall Syndicate to help drive investment toward the best, most effective medical research testing methods possible.
The COVID-19 pandemic is reshaping medicine, public health, and scientific research in an unprecedented way. This blog highlights three short-term and long-term impacts.
CCS's President and CEO, Dr. Aysha Akhtar, was interviewed on Pandemic Punditry Podcast episode titled "Animal Health is Human Health – Alternative to Animal Testing".
CCS Intern, Syama Patel, and Fellow, Mikalah Singer had a virtual “sit-down” with Dr. Kristen O’Halloran Cardinal from California Polytechnic State University to learn how students can get involved in innovative biomedical research.
Dr. Aysha Akhtar discusses the importance and effectiveness of human-specific biomedical research on "The Other Animals" Podcast.
Dr. Jarrod Bailey discussed "Minimizing Animal Models" with Dr. Ali Khademhosseini from The Terasaki Institute for Biomedical Innovation.
Academic researchers, along with representatives from the biotech industry and other stakeholders, meet to discuss the progress that has been made in in vitro biomedical sciences and technologies at the ACTC Conference.
Center for Contemporary Sciences' President and CEO, Dr. Aysha Akhtar, and Director of Science and Technology, Dr. Jarrod Bailey, discuss the importance of eliminating animal testing and focusing on innovative, biomedical research methods to improve human health.
This overview is intended to provide a snapshot of some salient and exciting developments and breakthroughs in various areas of biomedical research.
Researchers at Michigan State University (MSU) have grown the first functioning mini human heart model. As discussed in a recently published study, the model includes all the primary heart cell types, as well as functioning chamber structures and vascular tissue.
FOR IMMEDIATE RELEASE: Center for Contemporary Sciences Launches to Advance Human-Specific Research Models that will End Animal Testing.
In February 2019, a team of visionaries, scientists, and policy, non-profit and business leaders convened at a workshop at Harvard Law School to ask how can we help create a momentous shift in medical research in a way that betters human health and that replaces harmful experiments on animals.
The field of human-based research technologies is rapidly growing. For those interested in learning about where the latest developments are occurring, they must dig through volumes of literature and conduct in-depth and time-consuming internet and library searches. CCS is currently developing three Scientific Research Databases that will be freely available online.
The pandemic has created an immediate need to produce a safe vaccine—a process that researchers say can take upwards of 20 years. Is animal testing slowing us down?